KYAN Therapeutics – AI Platform for Combination Therapy, Clinical Stratification and Drug/Dose Recommendation

Combination Therapy

We drive the development of optimized combination therapies with existing lead molecules/compounds or INDs. Novel combinations are created more efficiently and effectively, at a fraction of the cost.

Media Optimization

We are able to quantifiably and objectively optimize media conditions, by identifying critical components at the right ratios to maximize desired bioprocesses and/or cell culture growth with lower expenditures.

Clinical Stratification

As a pre-clinical screening tool, our platform can investigate and explore patient response through ex vivo analysis, to enhance clinical trials with informed patient stratification and subpopulation grouping.

Drug Dose Recommendation

The right drugs, given at the wrong doses can result in ineffective treatment. KYAN reframes the dosing paradigm to determine dosages that can maximize efficacy and minimize toxicity simultaneously.

Recent News

Read about KYAN's recent developments below.

Co-Founders of KYAN Featured on The Straits Times

Co-Founders of KYAN Featured on The Straits Times

Posted in Company Updates by KYAN Team on June 25, 2019

Dean Ho and Edward Chow, both Co-Founders of KYAN Therapeutics have been featured on The Straits Times sharing their journey on driving novel therapies forward.

Dean Ho, Co-Founder of KYAN Therapeutics has been Elected a Member of the Prestigious NAI

Dean Ho, Co-Founder of KYAN Therapeutics has been Elected a Member of the Prestigious NAI

Posted in Company Updates by KYAN Team on January 10, 2019

KYAN is proud to announce that our Co-Founder, Prof. Dean Ho, has been elected a member of the prestigious National Academy of Inventors (NAI). He

Trethera Corporation and KYAN Therapeutics announce collaboration to develop artificial intelligence-driven optimization of solid cancer combination therapy

Trethera Corporation and KYAN Therapeutics announce collaboration to develop artificial intelligence-driven optimization of solid cancer combination therapy

Posted in Press Release by KYAN Team on October 26, 2018

LOS ANGELES and SINGAPORE, Oct. 25, 2018 /PRNewswire/ — Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for

Our Team

KYAN is staffed by team members who have decades of combined research and industry experience, with a singular mission to revolutionize the way patients are treated and therapies are developed.

Dean Ho

Dean Ho

Co-Founder

Dean Ho

Edward Chow

Edward Chow

Co-Founder

Edward Chow

Xianting Ding

Xianting Ding

Co-Founder

Chih-Ming Ho

Chih-Ming Ho

Co-Founder

Lisa M. Chow

Lisa M. Chow

COO & General Counsel

Masturah Rashid

Masturah Rashid

Scientist

Masturah Rashid

Shane Low

Shane Low

Business Developer

Shane Low